MMV and @deepmirror.bsky.social are advancing the next phase of Drug Design for Global Health (dd4gh), our open-access AI-powered drug discovery platform, with a new grant from the @gatesfoundation.bsky.social. Learn more: bit.ly/4beUFze

Archaeaophiles! Last chance to sign up as a virtual attendee for MBoA2026. It’s cheap and you will have access to all the talks include our archaea@50 celebration with a special guest: meetings.embo.org/event/26-arc...

Delighted to announce increasing our total seed round to $47M, with an additional $14M investment to support further development of our targeted protein degrader portfolio. Read more: shorturl.at/DfaXn

On Thursday 25 June, Andrea Testa and Dean Clift will be in Maine presenting at the Gordon Research Conference on Induced Proximity Modalities and Therapeutics. See below for more details ⬇️

Congrats to all 2026 #KavliPrize winners, especially to five ERC grantees: 🥇Vasily Belokurov from @cam.ac.uk, Amina Helmi @rug.nl & Rodrigo Ibata @cnrs.fr in #Astrophysics 🥇Christine Holt from @cam.ac.uk & Erin Schuman @maxplanck.de in #Neuroscience. 🔗 link.europa.eu/JkJwbg @kavliprize.bsky.social

Science really takes a village. Thrilled to share this with my friend @dudinlab.bsky.social, and with our brilliant and fearless teams, our collaborators around the world and our mentors - in my case a special shoutout to Buzz Baum, Jan Ellenberg and @monicabettencourt.bsky.social. 1/2

Three fully funded PhD opportunities available. Applicants from a range of academic backgrounds are encouraged to apply, but these opportunities are only available to applicants with Home fee status. Full details and how to apply: lstm.ac/studentships

This week, MMV and @dndi.org drug discovery teams came together to exchange ideas, common challenges and lessons learned across our research. From prioritizing promising compounds to advancing research in endemic countries, shared learning helps strengthen global health #innovation.

British science is behind 1 in 5 tools in the antimalarial R&D pipeline. Sustaining investment in UK malaria research could accelerate progress towards #malaria elimination while generating ripple effects across global health and economic development: bit.ly/49vc8T5

Wow, fully dropping the bird. Big move by @ec.europa.eu Publishers, where you at?

My letter to the Financial Times was published today on centralised vs devolved AI deployment. www.ft.com/content/75eb...

Relevant to #WomensHealthMonth!

Our latest blog takes a behind‑the‑scenes look at the experimental and structural biology work behind #OpenBind’s first data release - from protein production to crystallographic model building and refinement. https://loom.ly/Ydcti7A#OpenBind#StructuralBiology #Crystallography #OpenScience

🚀 Join us for the annual Milner Pitch Day, taking place ahead of #MilnerSymp26 🗓️ 6 July ⏰ 3–6pm 📍 Jesus College, Cambridge & online This showcase highlights promising pre-Series A companies from the Milner bio-incubator, local accelerators and international partners. 🔗 https://ow.ly/kykx50YzF4J

The latest blog from #OpenBind introduces a new structure–affinity dataset for the EV‑A71 2A protease, alongside reference benchmarks and guidance on how the community can use and evaluate it across docking, co‑folding, and affinity prediction. https://loom.ly/6xPIRUc#OpenBind#OpenScience #DrugDiscovery #AI

We’re delighted that TRIMTECH Therapeutics won 'Start-Up of the Year' at the 2026 Cambridge Independent Science & Technology Awards! Huge thanks to our team and supporters for helping drive our mission forward. Read more: lnkd.in/dJmmd_6S

Funding opportunity for women researchers in sub-Saharan Africa. 2026 L’Oréal-UNESCO For Women in Science Programme: • PhD & postdoc (SSA) • 30 PhD + 8 postdoc grants • €10k / €15k + leadership training Deadline: 15 May 2026 Apply: bit.ly/4cXDgv6

In the latest episode of the Guardian’s Science Weekly podcast, Professor Jonathan Ball speaks to Madeleine Finlay about suspected cases of hantavirus aboard a cruise ship travelling from Argentina to Cape Verde. Listen here: www.theguardian.com/science/audi...

At #RNPM26 in Brazil, MMV marked #WorldMalariaDay by discussing advances in tackling relapsing vivax #malaria. Brazil’s rollout of new tools like single-dose tafenoquine is helping redefine what’s possible for elimination.

We are deeply saddened by the passing of Dame Bridget Ogilvie, founding Chair of MMV. Her leadership helped establish MMV’s collaborative model & laid the foundation for a pipeline of antimalarials when they were needed most. Our thoughts are with her family and colleagues: bit.ly/3OVSJ70

Today we're launching the Open Source for Science Fund, a new multi-donor philanthropic fund by Renaissance Philanthropy, seeded by @biohub.org and @wellcometrust.bsky.social, with support from @kavlifoundation.org and @researchsoftware.bsky.social 🧵 os4science.org/news/open-so...

How are partnerships strengthening R&D capacity in Africa & what does this mean for #malaria? At a #WHSNairobi2026 side event, MMV & partners highlighted initiatives like RAFIKI, which is strengthening R&D in endemic countries while fostering new Africa/Europe collaborations. #WorldMalariaDay

United in the fight against #malaria and staying one step ahead of antimalarial drug resistance. Building on the momentum of #WorldMalariaDay, yesterday MMV and the RBM Partnership to End Malaria convened partners in Geneva to align and strengthen our collective response to drug resistance.

"Since 2010, the DDU malaria team, working with academic and industry partners, has been dedicated to discovering new medicines to treat and prevent malaria. One major success has been the discovery of Cabamiquine (DDD498)..." #NowWeCanNowWeMust #WorldMalariaDay #Research #EndMalaria #DDUAT20

We can end malaria in our lifetime. New tools like single-dose cures & long-acting injectables are coming, while countries scale up #vaccines & next-gen nets. But #malaria doesn’t wait. When funding drops, it resurges. Protect progress. Invest in what comes next. #WMD2026

British-backed science has helped build today’s antimalarial toolbox. Sustained support can get us closer to #ZeroMalaria. UK Parliamentarians explored tools behind progress against #malaria and innovations that can define what’s next at @malarianomoreuk.bsky.social #WorldMalariaDay event.

Children under five and pregnant women are the most at risk from malaria, accounting for the majority of the approximately 600,000 deaths each year worldwide. #NowWeCanNowWeMust #WorldMalariaDay #EndMalaria #GlobalHealth #HealthEquity #DrugDiscovery #InfectiousDiseases #PublicHealth #DDUAT20

🤍 White for health 💚 Green for prevention and awareness A small group in Geneva, part of a global team marking #WorldMalariaDay. We know this fight can be won through #partnership, #innovation and determination. #ZeroMalaria

#Malaria is preventable and treatable, yet it still takes lives every day. MMV-supported medicines have reached over 1 billion people since 1999. But the fight is changing. Drug resistance, climate pressure and funding challenges are putting progress at risk. #WorldMalariaDay

“It’s time we have the first approved and accessible African-invented antimalarial,” said MMV CEO Martin Fitchet at last year's @worldhealthsummit.bsky.social. With dd4gh, this ambition can start taking shape, expanding who gets to contribute to drug discovery 👉 bit.ly/4mdsWmI

bbc.com/audio/brand/... Now free for all archaea lovers to hear!

Our CEO Nicki Thompson will be joining the "Partnering with Big Pharma" panel at AngloNordic Life Science Conference XXII in London on Thursday. Reach out if you’d like to meet 📩 trimtechtherapeutics.com/contact/

How can we get #malaria elimination back on track as drug resistance rises? During a @who.int Regional Office for Africa webinar today, MMV's André-Marie Tchouatieu joined partners to highlight next-generation tools designed to stay ahead of resistance & improve treatment adherence. #WMD26

Is there a secret to getting 10 drugs approved? 🤔💊 Join the Founders Growth Community as they welcome Christoph Lengauer (Curie.Bio), sharing insights on bringing drugs to market and building in life sciences. 🗓️ Tomorrow, 3.30pm 📍 Deloitte, Cambridge 🔗 https://ow.ly/5br250YyHhX

Tune in to hear @lawrennd.bsky.social, Chair of ai@cam, contribute to the House of Commons Business and Trade Committee inquiry on #ArtificialIntelligence, #business and the future of the workforce. ➡️ Watch live from 14.30! parliamentlive.tv/event/index/...

Because in diseases like Chagas, leaving even a single parasite behind isn’t an option. At DDU, we developed a washout assay to determine if compounds can achieve complete parasite clearance. #DrugDiscovery #NTD #ChagasDisease #GlobalHealth #ScientificInnovation #NeglectedDiseases #Research

I am excited to be speaking at #BioTrinity2026 next Tuesday in London at the Wellcome Genome Campus showcase, focused on how biodata ventures are shaping the future of life sciences. I'll be sharing how we are tackling the data bottleneck in AI-driven drug discovery at @deepmirror.bsky.social

Different chemical coatings used on mosquito nets can affect how well they perform, which means that nets should be assessed on more than just their insecticide content alone, new research shows. Read more: lstmed.ac.uk/news/chemica...

🧬 Last call to join us in Cambridge for #EMBOMBoA26 (July 6th-10th)! We are just one week away from the registration and abstract submission deadline for the EMBO Workshop on the Molecular Biology of Archaea!

🚀 Turning Ideas into Therapies: a joint event with Cambridge Enterprise Connect with https://ow.ly/La0150YzF6R and explore how novel therapeutics are developed and funded, with insights from across biotech, pharma and venture. 🗓️ 16 April ⏰ 12:00–13:30 📍 JCBC, Cambridge 🔗 https://ow.ly/NACJ50YzF6P

After a year of co-creation with dozens of amazing global health researchers, we are thrilled to launch #dd4gh (Drug Design for Global Health) at @deepmirror.bsky.social, in partnership with Medicines for Malaria Venture @mmv.org. Learn more in the thread below, and apply for access here: dd4gh.ai

MMV & @deepmirror.bsky.social have launched dd4gh, an open-access AI platform giving researchers in LMICs access to advanced drug discovery tools. Designed to reduce costs & timelines, dd4gh is levelling the playing field for all scientists shaping research into #malaria & other diseases.

Researchers at Liverpool School of Tropical Medicine have identified a bacterium linked to noma, a devastating disease that affects young children. The discovery could enable earlier diagnosis and treatment, when it matters most. Read more: lstm.ac/4bId3RO

Contribution from Dr Ryan Greenhalgh, CTO and Dr Tushar Modi, Research Scientist. TLDR Cofolding models are only as strong as their data and securely shared protein–ligand datasets are now the bottleneck to use in drug-discovery programs. Read the full article: www.rsccicag.org/index_htm_fi...

Free registration for the 2026 #RDKit UGM (both in-person and online attendance) is now open: www.eventbrite.com/e/1985889262...

Cost and complexity put AI tools for drug discovery out of reach for many, but dd4gh is changing that. Watch Max Jakobs of @deepmirror.bsky.social explain how accessibility and pooled data can level the playing field for drug discovery researchers around the world.

Exchange programmes work best when expertise flows both ways. Meet Candice Soares de Melo & Jessica Thibaud, two South African researchers who spent time at MMV through the RAFIKI mentorship programme. See how the experience is shaping their work back home: bit.ly/4rMsltz

Next-gen #malaria prevention tools must be easy to administer & offer long-lasting protection. Long-acting injectables could provide at least 3 months of protection from a single dose. In Chicago, MMV & partners convened to align on the science & next steps 📸

Archaea hit prime time: www.bbc.co.uk/programmes/m...

AIchemy is BUSY 🚀 and the opportunities are stacking up! 💰 1 live funding opportunity (with Frontier Fund announcements coming 👀) 🎓 5 training & internship programmes 📅 14 events open for registration Funding. Training. Community. Momentum. Sign up to our newsletter and be part of it.